@article {Shaw2021.05.18.21257411, author = {Ashley R. Shaw and Jaime Perales-Puchalt and Ellie Johnson and Paul Espinoza-Kissell and Mariola Acosta-Rullan and Sarah Frederick and Anneka Lewis and Huan Chang and Jonathan Mahnken and Eric D. Vidoni}, title = {Representation of Racial and Ethnic Minority Populations in Dementia Prevention Trials: A Systematic Review}, elocation-id = {2021.05.18.21257411}, year = {2021}, doi = {10.1101/2021.05.18.21257411}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Despite older racial and ethnic minorities (REMs) being more likely to develop dementia they are underrepresented in clinical trials focused on neurological disorders. Inclusion of REMs in dementia prevention studies is vital to reducing the impact of disparities in dementia risk. We conducted a systematic review to characterize the number of REM enrolled in brain health and prevention randomized controlled trials (RCTs). RTCs published from January 1, 2004 to April 21, 2020 were included. Participants were normal cognitive adults aged 45 years and older who participated in a Phase II or Phase III U.S. based preventative trial. Analyses were performed to examine differences in trial characteristics between RCTs that did and those that did not report race/ethnicity and to calculate the pooled proportion of each racial/ethnic group in randomized brain healthy prevention trials. A total of 42 studies consisting of 100,748 participants were included in the final analyses. A total of 26 (62\%) reported some racial/ethnic identity data. The pooled proportion of REM participants was 0.256 (95\% CI, 0.191, 0.326). There is a lack of racial/ethnic reporting of participants and REMs remain underrepresented in brain health prevention RCTs.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the National Institute of Aging grant number P30AG035982.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The KUMC Human Research Protection Program (HRPP) deemed no requirement for IRB approval on 02/05/2021. This project involves a secondary analysis of data from the publish journals. The data analysis did not involve information about human subjects. For these reasons, the analysis does not involve human subjects and does not require IRB review.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data will be de-identified and available for other investigators at their request, in compliance with the NIH guidelines}, URL = {https://www.medrxiv.org/content/early/2021/05/20/2021.05.18.21257411}, eprint = {https://www.medrxiv.org/content/early/2021/05/20/2021.05.18.21257411.full.pdf}, journal = {medRxiv} }